Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma

Blood

Volumn 99, Issue 3, 2002, Pages 856-862

  Rambaldi, Alessandro ^{a,b,c,d,e,f,g,h,i,j}   Lazzari, Manuela ^{a,b,c,d,e,f,g,h,i,j}   Manzoni, Cristina ^{a,b,c,d,e,f,g,h,i,j}   Carlotti, Emanuela ^{a,b,c,d,e,f,g,h,i,j}   Arcaini, Luca ^{a,b,c,d,e,f,g,h,i,j}   Baccarani, Michele ^{a,b,c,d,e,f,g,h,i,j}   Barbui, Tiziano ^{a,b,c,d,e,f,g,h,i,j}   Bernasconi, Carlo ^{a,b,c,d,e,f,g,h,i,j}   Dastoli, Giuseppe ^{a,b,c,d,e,f,g,h,i,j}   Fuga, Giovanna ^{a,b,c,d,e,f,g,h,i,j}   Gamba, Enrica ^{a,b,c,d,e,f,g,h,i,j}   Gargantini, Livio ^{a,b,c,d,e,f,g,h,i,j}   Gattei, Valter ^{a,b,c,d,e,f,g,h,i,j}   Lauria, Francesco ^{a,b,c,d,e,f,g,h,i,j}   Lazzarino, Mario ^{a,b,c,d,e,f,g,h,i,j}   Mandelli, Franco ^{a,b,c,d,e,f,g,h,i,j}   Morra, Enrica ^{a,b,c,d,e,f,g,h,i,j}   Pulsoni, Alessandro ^{a,b,c,d,e,f,g,h,i,j}   Ribersani, Michela ^{a,b,c,d,e,f,g,h,i,j}   Rossi Ferrini, Pier Luigi ^{a,b,c,d,e,f,g,h,i,j}   Rupolo, Maurizio ^{a,b,c,d,e,f,g,h,i,j}   Tura, Sante ^{a,b,c,d,e,f,g,h,i,j}   Zagonel, Vittorina ^{a,b,c,d,e,f,g,h,i,j}   Zaja, Francesco ^{a,b,c,d,e,f,g,h,i,j}   Zinzani, Pierluigi ^{a,b,c,d,e,f,g,h,i,j}   Reato, Gigliola ^{a,b,c,d,e,f,g,h,i,j}   Foa, Robin ^{a,b,c,d,e,f,g,h,i,j}   more..

^a OSPEDALI RIUNITI   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e UNIVERSITY OF UDINE   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h ROCHE MILANO RICERCHE   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GENE PRODUCT; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0036464705     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.3.856     Document Type: Article

References (43)

1. Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases
2. t(14;18), a journey to eternity
3. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
4. Follicular lymphoma: Prognostic factors for response and survival
5. Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center
6. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up
7. All advanced stage non-Hodgkin's lymphoma with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment
8. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
9. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma
10. High dose therapy and autologous stem cell transplantation in follicular non-Hodgkin's lymphoma
11. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow
12. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma
13. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting
14. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
15. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies
16. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma
17. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma
18. Tumor specific idiotype vaccines in the treatment of patients with B cell lymphoma: Long term results of a clinical trial
19. Monoclonal antibody-based therapies for hematologic malignancies
20. Vaccine strategies in indolent lymphoma
21. Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: Emerging concepts of a tumor-targeted strategy
22. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
23. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
24. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
25. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
26. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
27. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
28. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
29. The clinical significance of molecular response in indolent follicular lymphomas
30. Correlation of Bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma
31. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response
32. Regression models and life tables
33. Nonparametric estimation from incomplete observations
34. Bone marrow of Non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion
35. Rituximab (IDEC-C2B8): Validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study
36. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a iow tumor burden: Clinical and molecular evaluation
37. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma
38. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy
39. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma
40. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
41. Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma
42. The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma
43. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals